Gyre Therapeutics (NASDAQ:GYRE) Sees Unusually-High Trading Volume

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) saw an uptick in trading volume on Monday . 32,014 shares changed hands during trading, a decline of 56% from the previous session’s volume of 72,870 shares.The stock last traded at $13.05 and had previously closed at $12.84.

Gyre Therapeutics Stock Up 11.8 %

The firm has a 50 day moving average of $12.23 and a 200-day moving average of $14.38.

Insider Buying and Selling

In related news, Director Nassim Usman sold 3,452 shares of the firm’s stock in a transaction on Friday, June 28th. The stock was sold at an average price of $12.00, for a total value of $41,424.00. Following the completion of the transaction, the director now owns 1,636 shares in the company, valued at approximately $19,632. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.92% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Gyre Therapeutics

Institutional investors have recently modified their holdings of the business. Rhumbline Advisers acquired a new stake in shares of Gyre Therapeutics during the 2nd quarter valued at about $123,000. Renaissance Technologies LLC acquired a new stake in shares of Gyre Therapeutics during the 2nd quarter valued at about $166,000. Bank of New York Mellon Corp acquired a new stake in shares of Gyre Therapeutics during the 2nd quarter valued at about $218,000. Finally, WINTON GROUP Ltd acquired a new stake in shares of Gyre Therapeutics during the 2nd quarter valued at about $220,000. 23.99% of the stock is currently owned by institutional investors and hedge funds.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.